Thymoquinone attenuates liver fibrosis via PI3K and TLR4 signaling pathways in activated hepatic stellate cells
- 12 January 2013
- journal article
- Published by Elsevier BV in International Immunopharmacology
- Vol. 15 (2), 275-281
- https://doi.org/10.1016/j.intimp.2012.12.020
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81160538, 30960511)
This publication has 34 references indexed in Scilit:
- Fibrogenic cell reversion underlies fibrosis regression in liverProceedings of the National Academy of Sciences of the United States of America, 2012
- Toll-Like Receptors in Liver Fibrosis: Cellular Crosstalk and MechanismsFrontiers in Physiology, 2012
- Molecular pathogenesis of hepatic fibrosis and current therapeutic approachesChemico-Biological Interactions, 2011
- Current status of novel antifibrotic therapies in patients with chronic liver diseaseTherapeutic Advances in Gastroenterology, 2011
- Targeting the Anti-Apoptotic Protein c-FLIP for Cancer TherapyCancers, 2011
- NF-κB in the liver—linking injury, fibrosis and hepatocellular carcinomaNature Reviews Gastroenterology & Hepatology, 2011
- Current Views of Toll-Like Receptor Signaling PathwaysGastroenterology Research and Practice, 2010
- PI3K/Akt activation is critical for early hepatic regeneration after partial hepatectomyAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2008
- Mechanisms of Hepatic FibrogenesisGastroenterology, 2008
- Pathogen Recognition and Innate ImmunityCell, 2006